ClinicalTrials.gg
Sign In
CompletedNCT03736278Updated Dec 11, 2019

Characteristics of Tuberculosis Infection in Rheumatic Disease

An observational study in Tuberculosis and Autoimmune Diseases, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-12-11.

Sponsored by National Taiwan University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
30
Ages
20 Years and older
Sex
All
01

Study summary

A retrospective study evaluating the characteristics of tuberculosis infection in patients of rheumatic disease.

02

Conditions studied

  • Tuberculosis
  • Autoimmune Diseases
03

In context

Tuberculosis

1,435 studies on the registry are indexed under Tuberculosis; 208 are open to participants now.

This study's enrollment of 30 is below the median of 240 across 427 observational studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,608 studies on the registry; 573 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Browse National Taiwan University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients of rheumatic disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patients with International Classification of Diseases (ICD) codes of rheumatic diseases during 2006-2017
  • Definite evidence of tuberculosis infection

Exclusion criteria

Exclusion Criteria:

  • HIV, malignancy, not follow-up rheumatic disease in National Taiwan University Hospital, younger than 20-year-old, refusing attend research
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
30 participants (actual)
Patient registry
No

Interventions

  • OtherNo intervention

    We group the patients according to the outcome (survival vs mortality)

06

What researchers measure

Primary outcomes

  1. Mortality

    Death of any cause (The definition of TB mortality from WHO is death of any cause during TB treatment.)

    Time frame: approximately 6 months

07

Study locations

1 site
  • National Taiwan University Hospital
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Nov 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2018
First posted
Nov 9, 2018
StartActual
Nov 10, 2018
Primary completionActual
Nov 30, 2018
CompletionActual
Sep 24, 2019
Last update
Dec 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03736278
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Nov 9, 2018
Start date
Nov 10, 2018
Primary completion
Nov 30, 2018
Completion
Sep 24, 2019
Last update
Dec 11, 2019

Study contacts

Chiao-Feng Cheng, MD
principal investigator · National Taiwan University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tuberculosis →

Other studies from this sponsor

National Taiwan University Hospital →

Start the discussion